This study will be a prospective, non-randomized evaluation of the Tritanium® Primary Acetabular Shell for primary total hip replacement (THR) with a cementless application in a consecutive series of patients who meet the eligibility criteria. The first 120 cases enrolled will receive the Tritanium® Primary Acetabular Shell. An additional 120 cases will receive the Tritanium® Primary Acetabular Shell with periapatite (PA), a biological coating.
The success rate, defined as freedom from acetabular revision for any reason, for hips implanted with the Tritanium® Primary Acetabular Shell, is no worse than for hips implanted with similar technology as reported in the literature and Trident® X3® Study historical control at 10 years postoperative.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01063751?cond=%22Arthritis%22&lup_s=07/28/2011&lup_d=30
